STAA · Staar Surgical Co
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY27 earnings call · Aug 12, 2026TL;DR. STAAR reported Q2 2026 net sales of $93.5 million, up 111% year-over-year, swung to net income of $8.1 million, and lifted cash to $181.5 million with no debt, driven by EVO+ adoption and sequential China share gains; management also flagged that Q3 2025 included a $25.9M one-time order that distorts year-over-year comparisons.
- + China sales grew over 100% Y/Y to $52.3M, 10% sequentially, fueled by EVO+ adoption and share gains
- + Gross margin expanded to 74.5% from 74.0%, reflecting Switzerland ramp benefit and lower manufacturing expenses
- + Americas grew 12% Y/Y with a second consecutive quarter above $6M in U.S. net sales
- + R&D pipeline advancing toward first-in-human studies on next-generation products with a new CTO being hired
- − Gross margin was negatively impacted by China tariffs on U.S.-manufactured product, expected to persist until end of 2026
- − EMEA reported sales declined 1% Y/Y due to Middle East conflicts
- − Q3 2026 year-over-year comparison is distorted by a $25.9M one-time 2024 order that will not repeat
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $20M | Q2 2026 | — |
| Adjusted EBITDA per diluted share non-GAAP | $0.39 | Q2 2026 | — |
| Americas sales growth Y/Y | 12% | Q2 2026 | — |
| APAC sales growth Y/Y | 189% | Q2 2026 | — |
| China sales | $52.3M | Q2 2026 | — |
| EMEA sales growth Y/Y | 1% | Q2 2026 | — |
| Global Sales Growth (Constant Currency) non-GAAP | 114.8% | Six Months Ended July 3, 2026 | — |
| Gross margin | 74.5% | Q2 2026 | — |
| Net sales excluding China | $41.2M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STAA
this stock
Staar Surgical Co
|
$1.03B | -3.1% | -23.7% | 256.4 | 9.2% |
|
ISRG
Intuitive Surgical Inc
|
$143.14B | -29.2% | +20.5% | 46.5 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.57B | — | +8.2% | — | 4.2% |
|
MDLN
Medline Inc.
|
$45.62B | -16.8% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.02B | -8.2% | +13.4% | 21.3 | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STAA | +17.3% | -3.2% | -15.4% | -1.0% | -3.1% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | +17.7% | -3.0% | -27.8% | -1.2% | -15.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.